LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Administration of Kainic Acid Differentially Alters Astrocyte Markers and Transiently Enhanced Phospho-tau Level in Adult Rat Hippocampus.

    Dahal, Abhishek / Govindarajan, Karthivashan / Kar, Satyabrata

    Neuroscience

    2023  Band 516, Seite(n) 27–41

    Abstract: Kainic acid (KA), an analogue of the excitatory neurotransmitter glutamate, when administered systemically can trigger seizures and neuronal loss in a manner that mirrors the neuropathology of human mesial temporal lobe epilepsy (mTLE), which affects ∼50 ...

    Abstract Kainic acid (KA), an analogue of the excitatory neurotransmitter glutamate, when administered systemically can trigger seizures and neuronal loss in a manner that mirrors the neuropathology of human mesial temporal lobe epilepsy (mTLE), which affects ∼50 million people globally. Evidence suggests that changes in astrocytes which precede neuronal damage play an important role in the degeneration of neurons and/or development of seizures in TLE pathogenesis. Additionally, a role for microtubule associated tau protein, involved in various neurodegenerative diseases including Alzheimer's disease, has also been suggested in the development of seizure and/or neurodegeneration in TLE pathogenesis. At present, possible alterations of different subtypes of astrocytes and their association, if any, with tau protein in TLE remain unclear. In this study, we evaluated alterations of different subtypes of astrocytes and phospho-/cleaved-tau levels in KA-treated rat model of TLE. Our results reveal that levels/expression of various astrocyte markers such as GFAP, vimentin, S100B, Aldh1L1, but not GS, are increased in the hippocampus of KA-treated rats. The levels/expression of both A1(C3+) and A2(S100A10+)-like astrocytes are also increased in KA-treated rats. Concurrently, the total (Tau1 and Tau5) and phospho-tau (AT270 and PHF1) levels are transiently enhanced following KA administration. Furthermore, the level/expression of cleaved-tau, which is apparent in a subset of GFAP-, S100B- and A2-positive astrocytes, are increased in KA-treated rats. These results, taken together, suggest a differential role for various astrocytic subpopulations and tau protein in the development of seizure and/or loss of neurons in KA model of TLE and possibly in human mTLE pathogenesis.
    Mesh-Begriff(e) Humans ; Adult ; Rats ; Animals ; Kainic Acid ; Astrocytes/metabolism ; tau Proteins/metabolism ; Hippocampus/metabolism ; Seizures/metabolism ; Epilepsy, Temporal Lobe/metabolism ; Disease Models, Animal
    Chemische Substanzen Kainic Acid (SIV03811UC) ; tau Proteins
    Sprache Englisch
    Erscheinungsdatum 2023-02-17
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196739-3
    ISSN 1873-7544 ; 0306-4522
    ISSN (online) 1873-7544
    ISSN 0306-4522
    DOI 10.1016/j.neuroscience.2023.02.010
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

    Anand, Bibin / Wu, Qi / Nakhaei-Nejad, Maryam / Karthivashan, Govindarajan / Dorosh, Lyudmyla / Amidian, Sara / Dahal, Abhishek / Li, Xiuju / Stepanova, Maria / Wille, Holger / Giuliani, Fabrizio / Kar, Satyabrata

    Bioactive materials

    2022  Band 17, Seite(n) 506–525

    Abstract: Alzheimer's disease (AD) is believed to be triggered by increased levels/aggregation of β-amyloid (Aβ) peptides. At present, there is no effective disease-modifying treatment for AD. Here, we evaluated the therapeutic potential of FDA-approved native ... ...

    Abstract Alzheimer's disease (AD) is believed to be triggered by increased levels/aggregation of β-amyloid (Aβ) peptides. At present, there is no effective disease-modifying treatment for AD. Here, we evaluated the therapeutic potential of FDA-approved native poly(d,l-lactide-
    Sprache Englisch
    Erscheinungsdatum 2022-07-15
    Erscheinungsland China
    Dokumenttyp Journal Article
    ISSN 2452-199X
    ISSN (online) 2452-199X
    DOI 10.1016/j.bioactmat.2022.05.030
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang